{"url_path":"/sec/atos/8-k/2026-05-08/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1488039/0001193125-26-213373-index.html","accession_number":"0001193125-26-213373","cik":"0001488039","ticker":"ATOS","issuer_name":"ATOSSA THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1488039/0001193125-26-213373-index.html","primary_entity_key":"0001488039","primary_entity_name":"ATOSSA THERAPEUTICS, INC."},"word_count":359,"has_tables":true,"body_markdown":"Item 5.07. Submission of Matters to a Vote of Security Holders.\n\n \n\nOn May 7, 2026, Atossa Therapeutics, Inc., a Delaware corporation (the “Company”), held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of the close of business on March 19, 2026, the record date for the Annual Meeting, there were 8,611,361 shares of common stock, par value $0.18 per share (the \"Common Stock\"), entitled to vote at the meeting.\n\nAt the Annual Meeting, each of the Company’s director nominees was elected and each of the other proposals voted on was approved. The final voting results are set forth below.\n\n \n\n(i)\nElection of Directors\n\nThe stockholders elected the three Class II directors by the following votes:\n\n \n\nNominee\n\nVotes\nFor\n\nVotes\nWithheld\n\nBroker\n\nNon-Votes\n\n•\nStephen J. Galli, M.D.\n\n1,726,410\n\n288,389\n\n2,222,160\n\n•\nRichard I. Steinhart\n\n1,730,171\n\n284,628\n\n2,222,160\n\n•\nTessa Cigler, M.D., M.P.H.\n\n1,750,694\n\n264,105\n\n2,222,160\n\n \n\n(ii)\nRatification of Independent Auditor\n\nThe stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 by the following votes:\n\n \n\nVotes\nFor\n\nVotes\nAgainst\n\nAbstentions\n\nBroker\n\nNon-Votes\n\n3,714,889\n\n370,496\n\n151,574\n\n0\n\n \n\n(iii)\nApproval of Amendment to the Amended and Restated Certificate of Incorporation to Effect a Reverse Stock Split of the Common Stock, if Deemed Necessary or Appropriate by the Board\n\n \n\nThe stockholders approved an amendment to the Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio from 2:1 to 20:1, inclusive, if determined necessary or appropriate by the Board, by the following votes:\n\n \n\nVotes\nFor\n\nVotes\nAgainst\n\nAbstentions\n\nBroker\n\nNon-Votes\n\n2,336,815\n\n1,866,873\n\n33,271\n\n0\n\n \n\n(iv)\nAdvisory Vote on Executive Compensation\n\n \n\nThe stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers by the following votes:\n\n \n\nVotes\nFor\n\nVotes\nAgainst\n\nAbstentions\n\nBroker\n\nNon-Votes\n\n1,530,390\n\n444,616\n\n39,793\n\n2,222,160\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n* * *\n\n \n\nSIGNATURES\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nAtossa Therapeutics, Inc.\n\nDate:\n\nMay 8, 2026\n\nBy:\n\n/s/ Mark J. Daniel\n\nMark J. Daniel\nChief Financial Officer"}